ClearNote Health
ClearNote Health develops epigenomic, blood-based diagnostics that detect cancer early by measuring 5-hydroxymethylcytosine (5hmC) signatures in cell-free DNA. The company operates an automated clinical laboratory, publishes peer-reviewed validation data, conducts clinical studies, and offers epigenomic profiling services to support translational drug development and biopharma partnerships.
Industries
Nr. of Employees
small (1-50)
ClearNote Health
155 Bovet Rd., Suite 405, San Mateo, CA 94402
Patents
Products
Pancreatic cancer cfDNA early detection test
A blood-based cfDNA assay that measures 5hmC epigenomic biomarkers to detect pancreatic cancer in high-risk patients.
Ovarian cancer cfDNA early detection test
A blood-based cfDNA assay using 5hmC biomarker analysis intended to detect ovarian cancer in women at elevated risk.
Pancreatic cancer cfDNA early detection test
A blood-based cfDNA assay that measures 5hmC epigenomic biomarkers to detect pancreatic cancer in high-risk patients.
Ovarian cancer cfDNA early detection test
A blood-based cfDNA assay using 5hmC biomarker analysis intended to detect ovarian cancer in women at elevated risk.
Services
Genome-wide 5hmC profiling of plasma cfDNA to support drug discovery, patient selection, monitoring of therapy response and resistance, and longitudinal translational studies.
Genome-wide 5hmC profiling of plasma cfDNA to support drug discovery, patient selection, monitoring of therapy response and resistance, and longitudinal translational studies.
Expertise Areas
- Epigenomic-based early cancer detection
- Liquid biopsy and cell-free DNA analysis
- Biomarker discovery and analytical validation
- Clinical laboratory operations and automation
Key Technologies
- 5-hydroxymethylcytosine (5hmC) profiling
- Cell-free DNA (cfDNA) analysis
- Whole-genome sequencing
- 5hmC enrichment workflows
News & Updates
Company to showcase latest advancements in early cancer detection testing at ESMO Congress 2025.
Poster and oral presentations on 5hmC profiling, treatment response monitoring, and diagnostic validation across multiple scientific meetings.
Peer-reviewed analytical validation of a pancreatic cancer early detection test using 5hmC signatures.
Received IVD approval in the UK for multi-cancer detection and ovarian cancer tests.
Received first in vitro diagnostic approval for a pancreatic cancer test.
Company previously received FDA Breakthrough Device Designation for a pancreatic cancer screening assay.
Company to showcase latest advancements in early cancer detection testing at ESMO Congress 2025.
Poster and oral presentations on 5hmC profiling, treatment response monitoring, and diagnostic validation across multiple scientific meetings.
Peer-reviewed analytical validation of a pancreatic cancer early detection test using 5hmC signatures.
Received IVD approval in the UK for multi-cancer detection and ovarian cancer tests.
Received first in vitro diagnostic approval for a pancreatic cancer test.
Company previously received FDA Breakthrough Device Designation for a pancreatic cancer screening assay.